Partitioning the sample into thousands of nanoliter-sized droplets allows each portion to undergo PCR independently. This physical separation helps distinguish droplets containing the target from those without it, which is important when a mutation or other nucleic-acid signal occurs at low frequency. The resulting positive and negative populations support precise quantification.
Endpoint fluorescence provides a binary readout: droplets are classified as positive or negative after amplification. The distribution of these two populations is then analyzed with Poisson statistics, which accounts for target molecules being randomly distributed among droplets. This calculation converts droplet counts into an absolute target concentration rather than relying only on amplification-cycle measurements.
Greater sensitivity and precision make ddPCR particularly useful when the target is rare relative to surrounding DNA or RNA. In cancer studies, that capability can reveal low-frequency mutations and quantify copy-number changes that may be difficult to resolve with less sensitive conventional amplification assays. It therefore supports analysis of subtle molecular differences in tumor-associated samples.
Unlike many conventional amplification assays, ddPCR determines target abundance from endpoint-positive and endpoint-negative droplet counts. The sample is separated into many independent reactions before fluorescence is measured, allowing rare targets to be evaluated through their distribution across droplets. This design provides the greater precision described for cancer-related nucleic acid quantification.
An analysis begins with a nucleic-acid sample that is divided into nanoliter-sized droplets. PCR proceeds independently in each droplet, followed by endpoint fluorescence measurement. The workflow then separates positive from negative droplets and applies Poisson statistics to their distribution. These stages produce an absolute concentration for the target in the analyzed sample.
ddPCR can provide an absolute target concentration and measurements of low-frequency mutations, copy-number changes, or circulating tumor DNA in blood. These outputs allow investigators to characterize tumor-associated molecular signals and compare their presence or abundance in ways relevant to tumor profiling and treatment-response studies.
Within cancer research, the method supports tumor profiling, treatment-response monitoring, and minimal residual disease assessment. Its ability to detect scarce molecular targets makes it useful when investigators need to follow tumor-associated DNA signals that may be present at low abundance. The same measurement capability also contributes to developing more sensitive molecular diagnostics.